Featured News

2023 promises to be a year full of robust research, advocacy, and education efforts on behalf of our patient community.

The month of May is Celiac Disease Awareness Month, and in an effort to bring celiac disease into the public eye, Marilyn G. Geller, Chief Executive Officer of the Celiac…

The Celiac Disease Foundation is in discussion with a team at the University of Colorado, Denver to develop the first-ever, FDA-approved pediatric PRO (patient-reported outcome tool).

We are determined to use every resource at our disposal, including strategic funding of research and advocacy, to help discover and bring to the celiac disease patient community therapeutic alternatives to the gluten-free diet.

The Celiac Disease Foundation achieved a number of critical milestones in 2020 in our efforts to accelerate the development of treatments and a cure for celiac disease.

I am thankful for your support, which has allowed the Celiac Disease Foundation to make a meaningful difference in the lives of our celiac community. 

Securing public and private health insurance coverage of Medical Nutrition Therapy (MNT) for celiac disease patients has been a long-time priority of the Celiac Disease Foundation.

We are pleased to announce our newest online resource for patients and caregivers to drive policy change to improve the health of those living with celiac disease and accelerate research: iAdvocate.

CDF has been approved for a $100,000 funding award through the Eugene Washington PCORI Engagement Awards program. The funds will support the community convening of patient advocates, researchers, and other key stakeholders to create a roadmap for patient advocate engagement in research.

On December 11, 2019, CEO Marilyn G. Geller was with Senator Blumenthal's legislative staff as Senator Richard Blumenthal (D-CT) introduced S.3021: Gluten in Medicine Disclosure Act of 2019 to the Senate. The Celiac Disease Foundation is proud to be a partner in this effort.